26 – 27 April 2021, Amsterdam (Netherlands)

 

MEETING OBJECTIVES

• Address the current challenges with surrogate endpoints in drug development and commercialisation
• Focus on a problem-solving aspect through debates and multi-stakeholder panel discussions.

PROGRAMME COMMITTEE

• Axel Glasmacher (CDDF, DE)
• Ralf Herold (EMA, NL)
• Chitkala Kalidas (Bayer, US)
• Claudia Hey (Merck Healthcare KGaA, DE)

TARGET AUDIENCE

The target is a multidisciplinary audience of academia representatives, EU and US regulatory bodies (EMA, FDA, National Agencies), pharmaceutical Industry, HTAs and patient advocates.

DRAFT PROGRAMME 

View the draft programme HERE

MEETING DATE

26 – 27 April 2021

MEETING VENUE 

TBC (Amsterdam, NL)